Yearly Archives: 2021

Adyen N.V. (ADYEN-AS, 2,599.50 EU) Tracking to Annualize $1 Trillion in Processed Volumes by Q3 2022.

https://www.adyen.com/investor-relations/h1-2021

Posted in Portfolio Model Subscription

BioNtech (BNTX-NASD, $453.65) Raises 2021 Net Vaccine Revenue Forecast Above Pfizer Indications.

In July, Pfizer, in its fiscal report, indicated that gross Covid-19 revenue sales were estimated at $33.5 billion US. This estimate was based upon contracts through mid-July signed with deliveries scheduled for 2021 totaling 2.1 billion doses. Pfizer and BioNtech

Posted in Portfolio Model Subscription

Novo Nordisk (NVO-NYSE, $99.48) Indicates Fast Launch of Wegovy, for Weight Loss.

From the second quarter, 2021 conference call: “The US launch of Wegovy has been extraordinarily fast. Following a six-month FDA review, Wegovy was approved on June 4, launched on June 10 and available to-or excuse me yes, available to patients

Posted in Portfolio Model Subscription

Global Market for mRNA Covid-19 Vaccines may be Larger than Anticipated, Given the Real World Impotence of “Not-mRNA” Vaccines.

Recent Brazilian allegations of financial irregularities pertaining to the purchase order of Bharat Pharmaceuticals covid-19 vaccine are troubling. The Bharat order has been cancelled. https://www.theguardian.com/world/2021/jun/29/brazil-cancels-covaxin-contract-after-serious-accusations-of-irregularities Allegations that Bharat diverted approximately 15% of the contract price, on a 20 million dose

Posted in Portfolio Model Subscription

Gnostic Capital Large Cap Global Portfolio Return of 17.5% for the Quarter Ended 06/30/2021.

For the quarter ended June 30th, 2021, the DJIA advanced by 4.5%, the S&P 500 increased by 8.2% and the NASDAQ Composite Index appreciated by 10.8%. US M2 money supply grew by 3.8% in the quarter. By way of comparison,

Posted in Portfolio Model Subscription
Recent Comments